中国介入影像与治疗学
中國介入影像與治療學
중국개입영상여치료학
CHINESE JOURNAL OF INTERVENTIONAL IMAGING AND THERAPY
2010年
2期
117-120
,共4页
肝肿瘤%经导管动脉化疗栓塞%缺氧诱导因子-1α%血管内皮细胞生长因子
肝腫瘤%經導管動脈化療栓塞%缺氧誘導因子-1α%血管內皮細胞生長因子
간종류%경도관동맥화료전새%결양유도인자-1α%혈관내피세포생장인자
Liver neoplasms%Transcatheter arterial chemoembolization%Hypoxia-inducible factor 1,alpha subunit%Vascular endothelial growth factor
目的 检测原发性肝癌(PLC)经导管动脉化疗栓塞(TACE)治疗前后血清缺氧诱导因子-1α(HIF-1α)及血管内皮细胞生长因子(VEGF)的含量.探讨其与TACE疗效及肿瘤复发、转移之间的相关性.方法 40例PLC患者接受TACE治疗前、术后1天、1周、1个月接受血清HIF-1α、VEGF含量检测,对照组为20名健康体检者.结果 40例PLC患者TACE术前血清HIF-1α、VEGF含量为(154.94±83.29)pg/ml、(264.00±148.10)pg/ml,明显高于对照组(P＜0.01);术后1天为(570.64±230.87)pg/ml,(362.07±102.25)pg/ml,较术前明显升高(P＜0.01);术后1周为(198.62±92.11)pg/ml、(283.52±145.46)pg/ml,较术后1天明显下降;术后1个月完全缓解(CR)组患者血清HIF-1α、VEGF含量为(133.96±57.02)pg/ml、(150.96±84.89)pg/ml,较术前明显降低.其中VEGF的含量差异有统计学意义(P＜0.05),而部分缓解(PR)和稳定(SD)组患者血清HIF-1α、VEGF含量为(255.74±123.44)pg/ml、(368.95±161.90)pg/ml,较术前明显升高(P＜0.05).PLC患者术前血清HIF-1α与VEGF含量呈正相关,血清HIF-1α与门静脉癌栓形成及肿瘤转移密切相关(P＜0.05);血清VEGF的含量与肿瘤临床分期、门脉癌栓及有无包膜密切相关.结论 通过检测PLC患者TACE治疗前后血清HIF-1α、VEGF含量,能为评估TACE疗效及判断肿瘤有无复发、转移等提供重要参考依据.
目的 檢測原髮性肝癌(PLC)經導管動脈化療栓塞(TACE)治療前後血清缺氧誘導因子-1α(HIF-1α)及血管內皮細胞生長因子(VEGF)的含量.探討其與TACE療效及腫瘤複髮、轉移之間的相關性.方法 40例PLC患者接受TACE治療前、術後1天、1週、1箇月接受血清HIF-1α、VEGF含量檢測,對照組為20名健康體檢者.結果 40例PLC患者TACE術前血清HIF-1α、VEGF含量為(154.94±83.29)pg/ml、(264.00±148.10)pg/ml,明顯高于對照組(P＜0.01);術後1天為(570.64±230.87)pg/ml,(362.07±102.25)pg/ml,較術前明顯升高(P＜0.01);術後1週為(198.62±92.11)pg/ml、(283.52±145.46)pg/ml,較術後1天明顯下降;術後1箇月完全緩解(CR)組患者血清HIF-1α、VEGF含量為(133.96±57.02)pg/ml、(150.96±84.89)pg/ml,較術前明顯降低.其中VEGF的含量差異有統計學意義(P＜0.05),而部分緩解(PR)和穩定(SD)組患者血清HIF-1α、VEGF含量為(255.74±123.44)pg/ml、(368.95±161.90)pg/ml,較術前明顯升高(P＜0.05).PLC患者術前血清HIF-1α與VEGF含量呈正相關,血清HIF-1α與門靜脈癌栓形成及腫瘤轉移密切相關(P＜0.05);血清VEGF的含量與腫瘤臨床分期、門脈癌栓及有無包膜密切相關.結論 通過檢測PLC患者TACE治療前後血清HIF-1α、VEGF含量,能為評估TACE療效及判斷腫瘤有無複髮、轉移等提供重要參攷依據.
목적 검측원발성간암(PLC)경도관동맥화료전새(TACE)치료전후혈청결양유도인자-1α(HIF-1α)급혈관내피세포생장인자(VEGF)적함량.탐토기여TACE료효급종류복발、전이지간적상관성.방법 40례PLC환자접수TACE치료전、술후1천、1주、1개월접수혈청HIF-1α、VEGF함량검측,대조조위20명건강체검자.결과 40례PLC환자TACE술전혈청HIF-1α、VEGF함량위(154.94±83.29)pg/ml、(264.00±148.10)pg/ml,명현고우대조조(P＜0.01);술후1천위(570.64±230.87)pg/ml,(362.07±102.25)pg/ml,교술전명현승고(P＜0.01);술후1주위(198.62±92.11)pg/ml、(283.52±145.46)pg/ml,교술후1천명현하강;술후1개월완전완해(CR)조환자혈청HIF-1α、VEGF함량위(133.96±57.02)pg/ml、(150.96±84.89)pg/ml,교술전명현강저.기중VEGF적함량차이유통계학의의(P＜0.05),이부분완해(PR)화은정(SD)조환자혈청HIF-1α、VEGF함량위(255.74±123.44)pg/ml、(368.95±161.90)pg/ml,교술전명현승고(P＜0.05).PLC환자술전혈청HIF-1α여VEGF함량정정상관,혈청HIF-1α여문정맥암전형성급종류전이밀절상관(P＜0.05);혈청VEGF적함량여종류림상분기、문맥암전급유무포막밀절상관.결론 통과검측PLC환자TACE치료전후혈청HIF-1α、VEGF함량,능위평고TACE료효급판단종류유무복발、전이등제공중요삼고의거.
Objective To investigate the expression and correlation of serum hypoxia inducible factor-1α (HIF-1α) and vascular endothelial growth factor (VEGF) level pre-and post-transcatheter arterial chemoembolization (TACE) in patients with primary liver cancer (PLC) .Methods Expression of serum HIF-1α and VEGF were studied in 40 patients of PLC pre-and 1 day,1 week,1 month post-TACE and 20 healthy volunteers (as control group) .Results The expression of HIF-1α and VEGF was (154.94±83.29) pg/ml and (264.00±148.10) pg/ml before TACE,higher than those in control group (P＜0.01) .The expression of HIF-1α and VEGF was (570.64±230.87) pg/ml and (362.07±102.25) pg/ml in PLC patients 1 day post-TACE,higher than those before TACE (P＜0.01) ; (198.62±92.11) pg/ml,and (283.52±145.46) pg/ml 1 week post-TACE; (133.96±57.02) pg/ml and (150.96±84.89) pg/ml in the complete response (CR) group 1 month after TACE, (255.74±123.44) pg/ml and (368.95±161.90) pg/ml in partial response (PR) and stable disease (SD) group (P＜0.05) .The expression of serum HIF-1α was positively correlated with VEGF before TACE,and the serum HIF-1α also correlated with portal vein tumor thrombosis and metastasis.Serum VEGF was also correlated with clinical stage,portal vein tumor thrombosis and capsule.Conclusion The expression of serum HIF-1α and VEGF plays an important role in relapse of tumor,and contributes to the evaluation of the efficacy of TACE and metastasis of PLC.
